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AbstrACt
Introduction Severe acute pancreatitis (AP) requiring 
critical care admission (ccAP) impacts negatively on long-
term survival.
Objective To document organ-specific new morbidity and 
identify risk factors associated with premature mortality 
after an episode of ccAP.
Design Cohort study.
setting Electronic healthcare registries in Scotland.
Participants The ccAP cohort included 1471 patients 
admitted to critical care with AP between 1 January 2008 
and 31 December 2010 followed up until 31 December 
2014. The population cohort included 3450 individuals 
from the general population of Scotland frequency-
matched for age, sex and social deprivation.
Methods Record linkage of routinely collected electronic 
health data with population matching.
Primary and secondary outcome measures Patient 
demographics, comorbidity (Charlson Comorbidity Index), 
acute physiology, organ support and other critical care 
data were linked to records of mortality (death certificate 
data) and new-onset morbidity. Kaplan-Meier and Cox 
regression analyses were used to identify risk factors 
associated with mortality.
results 310 patients with AP died during the index 
admission. Outcomes were not ascertained for five 
patients, and the deprivation quintile was not known 
for six patients. 340 of 1150 patients in the resulting 
postdischarge ccAP cohort died during the follow-up 
period. Greater comorbidity measured by the Charlson 
score, prior to ccAP, negatively influenced survival in the 
hospital and after discharge. The odds of developing new-
onset diabetes mellitus after ccAP compared with the 
general population were 10.70 (95% CI 5.74 to 19.94). 
A new diagnosis of myocardial infarction, stroke, heart 
failure, liver disease, peptic ulcer, renal failure, cancer, 
peripheral vascular disease and lung disease was more 
frequent in the ccAP cohort than in the general population.
Conclusions The persistent deleterious impact of severe 
AP on long-term outcome and survival is multifactorial in 
origin, influenced by pre-existing patient characteristics 
and acute episode features. Further mechanistic and 
epidemiological investigation is warranted.
IntrODuCtIOn 
Acute pancreatitis (AP) is the most common 
gastrointestinal cause of emergency hospital 
admission. The incidence of AP is increasing, 
and in Scotland is 31.8 per 100 000.1–5 
The overall case fatality in AP is 5%.5 Although 
most cases are mild and self-limiting, one in 
four patients with AP develops multiple organ 
dysfunction syndrome (AP-MODS) and 
requires critical care admission.6 AP-MODS 
is the single most important determinant of 
death from AP,7 with mortality in patients 
with AP-MODS reaching 21.7%.5 Recently, 
we reported that AP-MODS has detrimental 
consequences even for those who survive the 
acute episode, who have a reduced overall 
strengths and limitations of this study
 ► This study is on a large contemporary cohort of pa-
tients with acute pancreatitis (AP) covering a nation-
al population (Scotland).
 ► Through secure record linkage, postdischarge criti-
cal care AP morbidity data are analysed in the con-
text of episode-specific and pre-existing morbidity 
data.
 ► The use of pre-existing national databases resulted 
in low, but not negligible, amounts of missing data.
 ► The amount of missing data might have been further 
reduced had it been possible to prospectively cap-
ture all primary data.
 ► Only gallstone aetiology could be specifically ex-
amined due to data inaccuracies in the recording of 
other aetiologies of AP, specifically alcohol excess.
 ► The analysis of existing and new comorbidities was 
limited by the relatively small proportion of patients 
affected by each comorbidity, and because comor-
bidities derived from Scottish Morbidity Record 01 
data only reveal diagnoses made at the time of a 
hospital admission and therefore are an underesti-
mate of the true population prevalence. 
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survival compared with AP without MODS.8 Prevention 
of AP-MODS in humans remains an elusive goal,9 and it 
is therefore important to characterise the lasting impact 
on survivors to help maximise their long-term well-being.
AP has many potential causes, of which gallstones and 
alcohol are most frequently implicated.6 10 The resulting 
inflammatory reaction within the pancreas may become 
overamplified and precipitate a systemic inflammatory 
response, shock and organ dysfunction.6 10–13 There is 
marked interindividual heterogeneity in the number of 
organ systems involved, and AP-MODS can affect any 
organ system, with the respiratory and renal systems most 
frequently affected.14–17 Moreover, the severity of organ 
dysfunction is highly variable, and interventions including 
invasive ventilation and renal replacement therapy can be 
required for durations raging from 1 day to 10 weeks.18 19 
AP-MODS determines mortality during the index admis-
sion,20 but it is not certain which organ-specific failures are 
particularly associated with deterioration to death. One 
study linked hepatic and renal failures with the highest 
mortality risk,19 whereas another placed greater negative 
influence after failure of the cardiovascular, pulmonary 
and gastrointestinal systems.16
Importantly, it is not completely understood which 
specific organ deficits may persist in survivors of 
AP-MODS. AP-MODS has been associated with an 
increased incidence of diabetes in AP survivors,15 21 22 
and age and working status are important in predicting 
recovery of quality of life and functional capacity.21 More-
over, given the heterogeneity of the course of AP-MODS, 
it is unclear if a subgroup of AP-MODS survivors is at 
particularly high risk of a poor outcome. In the absence 
of an intervention to prevent AP-MODS, a deeper under-
standing of the persistent pathophysiological impact left 
by AP-MODS is needed. Therefore, our aim in this study 
was to integrate routinely collected data to investigate the 
causes and predictors of mortality in the years following 
an episode of AP requiring critical care admission.
MethODs
study design, data security and patient confidentiality
This retrospective cohort study was conducted in collab-
oration with Electronic Data Research and Innovation 
Service to facilitate record linkage from multiple national 
databases. Information governance and security protocols 
were adhered throughout the investigation. All primary 
data were stored securely. Individual informed consent 
was not required or sought for this study.
Patient and public involvement
We work closely with our patient and public involvement 
group, APPLe (Acute Pancreatitis Patient Liaison), to 
develop our research projects and strategies. This study 
received general input from members of APPLe as part 
of a consortium building workshop for the APPreSci 
Consortium (Acute Pancreatitis Precision Science, www. 
appresci. com), but APPLe was not involved in the data 
collection, analysis or manuscript preparation.
Patient identification and data collection
All data were handled according to the Charter for Safe 
Havens in Scotland.23 The Scottish Intensive Care Society 
Audit Group (SICSAG) WardWatcher database24 was used 
to identify all patients admitted to critical care with AP 
between 1 January 2008 and 31 December 2010. AP was 
defined as any admission to critical care where the primary 
diagnosis coded by the intensive care senior clinician 
on duty was recorded as International Classification of 
Diseases, 10th Revision (ICD-10) classification K85 (acute 
pancreatitis). Where an individual was admitted with AP 
on more than one occasion, the earliest AP episode was 
taken as the index episode. There were no additional 
exclusion criteria. We performed a record linkage anal-
ysis of the Scottish Morbidity Record (SMR) 01 (general 
acute inpatient and day cases), General Register Office 
death records, SICSAG (critical care) and Commu-
nity Health Index (CHI) databases. Causes of death of 
the general population of Scotland were obtained from 
National Records of Scotland Vital Events Tables.25 
Patient outcomes were recorded from the date of their 
index admission until the end of the follow-up period on 
31 December 2014. Those lost to follow-up were censored 
at the point of last known contact. Prior to analysis, data 
records were linked using unique patient identifiers in 
order to maintain confidentiality.
Variables of interest
The primary outcome of interest was death. The 
secondary outcomes were cause of death and new-onset 
morbidity. The following details of the index AP episode 
were recorded for each patient: gallstone aetiology (from 
SMR01 data), APACHE II score (Acute Physiology and 
Chronic Health Evaluation score, V.2), length of stay in 
critical care, level of critical care admission (high-depen-
dency unit [HDU] or intensive care unit [ICU]),26 and 
the requirement for renal replacement therapy, invasive 
ventilation, non-invasive ventilation, continuous positive 
airways pressure or vasopressor support (all from SICSAG 
data). In addition, the following patient characteristics 
were recorded: age on admission (from SICSAG), gender 
(from the CHI database), Scottish Index of Multiple 
Deprivation, Charlson score for comorbidity (calculated 
from the SMR01 records for each patient in the 5 years 
prior to admission)27 and the number of comorbid condi-
tions contributing to the Charlson score. The cause of 
death was obtained for each deceased patient and sorted 
according to the ICD-10 code into one of five categories: 
cardiovascular/circulatory, respiratory, neoplasia, diges-
tive/metabolic or other causes, as shown in online supple-
mentary table 1.
statistical analysis
IBM SPSS Statistics V.21 was used for all analyses. Cate-
gorical variables were reported as the absolute frequency 
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and percentage. Continuous variables were reported as 
the mean±SD or the median±IQR. Kaplan-Meier anal-
ysis was used to demonstrate survival with respect to 
demographic and clinical factors, with the significance 
of differences assessed using the log-rank (Mantel-Cox) 
test. Survival was calculated as the time from the index 
admission to the hospital with AP to death; analyses and 
plots were done for the whole cohort, and for the cohort 
excluding those members who died during the index 
episode of AP in order to allow for analysis of long-term 
outcomes in survivors of the index episode, as specified in 
the Results section and in the figures.
The proportional hazards assumption was tested 
using log(-log) plots of the survival function over time, 
to confirm that the curves were approximately parallel. 
A multivariate Cox regression model was constructed 
to account for potential interactions between predictor 
variables. Covariates were added to the model using 
a forward stepwise method. At each step, the covariate 
found to be most significant was retained in the model. 
The threshold for retention in the models created using 
SPSS was p=0.01. After each addition, the covariates 
already present in the model were tested for removal 
depending on the significance of the likelihood ratio with 
and without each covariate.
A p value of 0.05 or less was considered significant. 
Where multiple pairwise comparisons were made—
age group (<20, 20–29, 30–39, 40–49, 50–59, 60–69, 
70–79, >80 years), Charlson score (0, 1, 2, 3, 4+), number 
of comorbid conditions (0, 1, 2, 3+)—the Bonferroni 
correction was applied to account for the quantity of 
comparisons being made.
secondary analysis of associated comorbidities
A control group was created from the general popula-
tion using the CHI database register of all patients in 
Figure 1 Study population demographics. Visual representation of the demographic characteristics for the study cohort 
(n=1471 patients) with stacked bar charts. In all panels, the absolute number of patients per variable category is charted: in 
red are patients who died in the hospital, those who died postdischarge are in blue and those surviving to the end of follow-
up are in grey. The following attributes of the cohort are depicted sequentially in each respective panel: (A) Scottish Index of 
Multiple Deprivation, (B) Charlson score, (C) gender, (D) age (transformed to a categorical variable) and (E) number of comorbid 
conditions contributing to the Charlson score.
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Scotland. Controls were frequency-matched on depri-
vation quintile, age (by year of birth) and sex. Three 
controls were selected for every member of the exposed 
group. Comorbidities at index admission for AP were 
obtained from the SMR01 computerised acute hospital 
discharge records (day cases or inpatients) in the 
5-year look-back period from date of admission for the 
index AP episode. Comorbidities that developed after 
discharge were ascertained from admissions after the 
index admission for AP up to 31 December 2014. The 
comorbidities that developed after the index event were 
then compared in the exposed and unexposed groups 
with a two-sample z test. We calculated the OR (and 
95% CI) of developing each comorbidity given previous 
admission for AP needing critical care, compared with 
people with no previous AP admission.
Table 1 Demographic characteristics of the ccAP cohort
Died during 
index admission % of total
Survived index 
admission % of total
Died after 
hospital 
discharge % of total
Gender 
  Male 175 21 475 58 175 21
  Female 135 21 341 53 165 26
Age group 
  <20 0 0 19 95 1 5
  20–29 7 9 66 84 6 8
  30–39 13 9 112 78 19 13
  40–49 22 11 141 72 34 17
  50–59 47 19 157 62 49 19
  60–69 72 25 143 49 75 26
  70–79 83 27 135 44 86 28
  80+ 66 37 43 24 70 39
Scottish Index of Multiple Deprivation quintile 
  1—most 
deprived
86 20 257 59 92 21
  2 75 22 179 52 90 26
  3 54 21 141 54 67 26
  4 51 23 126 56 49 22
  5—least 
deprived
44 23 107 55 42 22
  Not known 0 0 6 100 0 0
Charlson Comorbidity Index 
  0 219 21 666 63 167 16
  1 41 20 91 44 77 37
  2 38 25 41 27 71 47
  3 7 18 12 32 19 50
  4+ 5 36 3 21 6 43
  Not known 0 0 3 100 0 0
Number of comorbid conditions contributing to the Charlson Comorbidity Index 
  0 219 21 666 63 167 16
  1 70 21 126 38 136 41
  2 18 28 16 25 31 48
  3+ 3 21 5 36 6 43
  Not known 0 0 3 100 0 0
The absolute number of patients and row percentages per each category for the following variables of interest are presented: gender, age 
group, Scottish Index of Multiple Deprivation,43 Charlson Comorbidity Index27 and the number of comorbid conditions contributing to the 
Charlson Comorbidity Index.
ccAP, critical care requiring acute pancreatitis.
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Between 1 January 2008 and 31 December 2010, 1471 
patients were admitted to HDU or ICU with AP. The length 
of the follow-up period ranged from 4.0 to 7.0 years. The 
median duration of follow-up from the date of index admis-
sion for all patients with AP was 4.4 years (IQR 0.6–5.6 
years) and 4.9 years (IQR 4.0–5.8 years) when patients 
who died in the hospital during the index admission were 
excluded. Sixteen patients moved to another country and 
were censored at the point of last known contact. Figure 1 
outlines the demographics of the study population. Demo-
graphic data for the cohort are presented in table 1.
During the follow-up period, 651 of 1471 (44.3%) 
patients died. Of 651 deaths, 310 (47.8%) occurred 
during the index admission; the outcome of 5 was not 
known and the deprivation quintile for 6 other patients 
was not known. The postdischarge critical care AP (ccAP) 
cohort therefore included 1150 patients, of whom 340 
died during the follow-up period. As over half of the 
study cohort survived to the end of follow-up, the median 
survival time could not be determined. The mean (±SD) 
survival time in the whole cohort was 4.4±0.1 years and 
5.6±0.1 years once in-hospital deaths were excluded.
Cause of death
In the postdischarge ccAP cohort, neoplasms were the 
leading cause of death (27.9%), followed by cardiovas-
cular (27.1%) and digestive/metabolic deaths (25.9%) 
(figure 2). Other causes contributed only 5.3% of the 
total. This contrasted with the general population of 
Scotland for which a lower proportion of deaths were 
attributed to digestive causes (7.3%), while a markedly 
greater proportion of the general population controls 
were due to other causes (21.0%) (figure 2).
Predictors of mortality in the postdischarge cohort
Independent negative risk factors for long-term survival 
included age (online supplementary figure 1), a 
Charlson score of 1 or greater (table 2 and figure 3A), 
and the number of comorbid conditions contributing to 
the Charlson score (table 2 and figure 3B). Survival did 
not differ significantly with the degree of social depriva-
tion (online supplementary figure 2). Female gender was 
associated with a shorter survival on univariate analysis, 
but gender as a risk factor on the multivariate analysis 
was not significant (table 3 and figure 3C). Gallstone aeti-
ology was associated with a lower mortality after discharge 
(table 3). Comparison with analyses that included in-hos-
pital deaths indicated that these differences emerged 
postdischarge (online supplementary figures 1–6). Multi-
variate Cox regression analysis also identified increased 
age group and Charlson comorbidity score as poor prog-
nostic factors (table 3).
A significant relationship was observed between the 
requirement for renal replacement therapy, respiratory 
or circulatory support and an increased risk of death 
when in-hospital deaths were included (online supple-
mentary figures 7–11). However, no correlation between 
mortality and any of the aforementioned medical inter-
ventions, or gallstone aetiology, was observed when 
considering only postdischarge outcomes (online supple-
mentary figures 6–11). Long-term survival of those 
who survived the index episode was significantly better 
where the length of stay in critical care during the index 
episode exceeded 20 days, compared with admissions of 
0–4 or 10–19 days (figure 4A). The critical care setting 
was important—patients with AP-MODS admitted to 
ICU, and who survived that event, had better long-term 
survival compared with those who were admitted to HDU 
and survived (figure 4B,C and table 2).
Development of new specific comorbidities
Patients in the ccAP cohort were significantly more likely 
to develop a range of cardiovascular, gastrointestinal, 
pulmonary and neoplastic conditions than matched 
controls (table 4). A particularly high risk of developing 
new-onset diabetes was noted (OR 10.70, 95% CI 5.74 
to 19.94), with 3.9% of the ccAP cohort developing new 
diabetes during the follow-up period compared with 0.4% 
of the matched control group. The risk of developing renal 
disease requiring hospital admission was also markedly 
increased (OR 9.15, 95% CI 2.95 to 28.43), but whether 
this was confounded by new or existing diabetes could 
not be ascertained, and the number of people affected 
by renal disease was small in both cohorts. The risks for 
developing other comorbidities are presented in table 4.
In addition to evaluating the risk of new-onset comor-
bidity, we examined whether the baseline comorbidities 
Figure 2 Comparison of the causes of death between 
the ccAP cohort and the general population. Bar chart of 
the causes of death of the postdischarge ccAP cohort (341 
deaths—blue colour) and of those of matched controls 
from the general population of Scotland (381 060 deaths—
red colour). The causes of death have been grouped into 
one of the following categories, according to the ICD-10 
code: cardiovascular/circulatory, respiratory, neoplasia, 
digestive/metabolic or other causes (online supplementary 
table 1). ccAP, acute pancreatitis requiring critical care 
admission; ICD-10, International Classification of Diseases, 
10th Revision. 
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of the population who experience an episode of AP might 
be different from the general population (table 4). At the 
time of presentation with their index episode, patients 
with AP needing critical care were significantly more 
likely to have existing comorbidities that included cardiac, 
lung, renal or peripheral vascular disease, heart failure, 
connective tissue disorders, peptic ulcers, and cancer 
than matched general population controls. ccAP there-
fore appears to be a feature associated with the members 
of the population who are already less healthy.
DIsCussIOn
This retrospective data linkage cohort study aims to inves-
tigate the causes and predictors of mortality in the years 
following an episode of AP requiring critical care admis-
sion. In so doing, statistically significant differences in 
frequency of the causes of death have been demonstrated 
between the ccAP patient cohort and the general popu-
lation. In addition, the results indicate that long-term 
prognosis after a critical care admission for AP is influ-
enced to a greater extent by age at the time of index 
AP admission and existing comorbidity than by specific 
features of the index AP episode. New-onset comor-
bidity, particularly diabetes, is more frequent following 
ccAP than in the general population. We acknowledge 
that ccAP patients may have additional diagnoses made 
because these individuals seek more frequent contact 
with healthcare and therefore have the opportunity to 
get diagnosed with comorbidities. Furthermore, comor-
bidities derived from the SMR01 data only reveal diag-
noses made at the time of a hospital admission and are 
therefore an underestimate of the true population prev-
alence. From our analysis it is not possible to discern 
whether those individuals were destined to develop those 
comorbidities regardless of their episode of AP, espe-
cially given that the AP cohort is less healthy overall than 
the matched general population. A similar association 
between MODS and mortality has been demonstrated 
Table 2 Predictors of long-term mortality—univariate regression analysis
Risk factor n HR 95% CI P value
Age Under 20 20 –
   (reference <20 
years)
20–29 72 1.6 0.2 to 13.1 0.674
30–39 131 2.9 0.4 to 21.8 0.296
40–49 175 3.9 0.5 to 28.5 0.180
50–59 206 5.0 0.7 to 36.5 0.110
60–69 218 7.9 1.1 to 57.0 0.040
70–79 221 8.7 1.2 to 62.4 0.032
80+ 113 17.3 2.4 to 124.4 0.005
Gender Male 650 –
  (reference male) Female 506 1.2 1.0 to 1.5 0.049
Charlson score 0 833 –
  (reference 0) 1 168 2.6 2.0 to 3.4 <0.001
2 112 4.7 3.6 to 6.2 <0.001
3 31 3.8 2.4 to 6.1 <0.001
4 or more 9 5.3 2.4 to 12.0 <0.001
Number of comorbid 
conditions
0 833 –
  (reference 0) 1 262 3.2 2.6 to 4.0 <0.001
2 47 4.5 3.0 to 6.7 <0.001
3 11 3.3 1.5 to 7.5 0.004
Length of stay Less than 20 days 1079 –
  (reference <20 
days) 
Longer than 20 days 77 0.4 0.2 to 0.8 0.006
Level of critical care ICU 251 –
  (reference ICU) HDU 905 1.2 1.0 to 1.4 0.019
The HR, 95% CI and p value of Wald’s test are presented for each variable found to significantly affect postdischarge survival on 
univariate regression analysis. P<0.05 was considered significant. The reference category for each variable is appended. Age has 
been transformed to a categorical variable for the purposes of the analysis.
 ccAP, acute pancreatitis requiring critical care admission; HDU, high-dependency unit; ICU, intensive care unit; n, number of  
patients  per category. 
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in patients who have sustained trauma.28 Our results 
support our previously observed concept that ccAP is 
associated with a persistent deleterious impact on survi-
vors. Interindividual heterogeneity in the clinical course 
of the AP critical care episode was not associated with any 
organ-specific long-term outcomes in this analysis, but we 
acknowledge that our approach was limited in the ability 
to discriminate these with certainty.
Together, these findings lend weight to the hypoth-
esis that severe AP episodes do not fully resolve, with 
particular emphasis on the impact of the associated 
systemic dysfunction. Our study has added data and 
analysis to underpin this concept by investigating the 
specific details of the deleterious legacy of ccAP. Given 
that the variation in causes of death is largely due to an 
increased proportion of deaths from metabolic disease, 
it is reasonable to infer that AP mediates the long-term 
effects primarily through ongoing metabolic pathology. 
This result concurs with outcomes in a Danish cohort that 
demonstrated a marked increase in deaths from digestive 
system causes in AP survivors compared with the general 
population.29 The exact mechanisms underpinning the 
metabolic disturbance remain to be elucidated and will 
almost certainly require a prospective experimental medi-
cine study. Taken together, the reported high incidence 
of diabetes mellitus after AP, the correlation of AP severity 
with lasting pancreatic exocrine dysfunction (as shown by 
others) and the negative effect of exocrine pancreatic 
insufficiency suggest that impairment of the endocrine 
and exocrine pancreas is the main driver of the lasting 
overall dysfunction.15 21 22 Additionally, it is reasonable 
to expect that aspects of the acute systemic dysfunction 
associated with MODS, for example, insulin resistance 
and mitochondrial dysfunction, fail to resolve entirely,30 
although we have not tested this experimentally in this 
study.
Identifying predictors of postdischarge mortality will 
facilitate appropriate targeting of preventative interven-
tions. The identification of greater pre-existing comor-
bidity as a key negative predictive factor is consistent with 
previous research correlating more extensive comorbid 
disease with a worse prognosis after critical illness.31 In 
the present study, our observation that postdischarge 
outcomes were better for ICU than HDU patients by 
univariate analysis could be explained by comorbidity—
those requiring ICU admission theoretically experience 
the worst AP episodes, and therefore only relatively fitter 
Figure 3 Postdischarge survival of ccAP patients—patient characteristics. Kaplan-Meier survival plots for postdischarge 
ccAP patients, grouped by (A) Charlson score, (B) number of comorbid conditions contributing to each calculated Charlson 
score and (C) gender. The numbers of patients at risk at each time point are displayed. For each plot, in-hospital deaths have 
been excluded and time 0 corresponds to point of discharge. Vertical dashes represent right-censored patients. ccAP, acute 
pancreatitis requiring critical care admission. 
Table 3 Final model of prognostic factors of postdischarge 
mortality
Risk factor HR 95% CI P value
Age* 1.0 1.0 to 1.1 <0.001
Charlson score 1.5 1.4 to 1.7 <0.001
Female gender 1.2 1.0 to 1.5 0.058
Gallstone 
aetiology
0.7 0.6 to 0.9 0.003
The HR, 95% CI and p value of Wald’s test are presented for each 
variable retained in the final multivariate Cox regression model. 
P<0.05 was considered significant.
Control variables not in the final model: renal replacement therapy, 
invasive ventilation, non-invasive ventilation, vasopressor use and 
Scottish Index of Multiple Deprivation.
*Age group as defined in table 2.
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individuals may survive to discharge. In contrast, those 
with greater comorbidity, and hence a higher risk of 
later mortality, may survive an AP episode managed in 
HDU. We acknowledge that the preceding statement is 
somewhat speculative, despite being highly plausible. A 
similar argument may explain the association of better 
Figure 4 Postdischarge survival of ccAP patients—nature of the critical care admission. Kaplan-Meier survival plots for 
postdischarge ccAP patients, grouped by (A) duration of critical care admission, (B) level of critical care (all ccAP patients) 
and (C) level of critical care (post-ccAP patients, excluding in-hospital deaths). The numbers of patients at risk at each time 
point are displayed for each plot. Vertical dashes represent right-censored patients. ccAP, acute pancreatitis requiring critical 
care admission; HDU, high-dependency unit; ICU, intensive care unit. 
Table 4 Baseline comorbid status and risk of developing new comorbidities after the index AP episode
Comorbidity
Comorbidities at SICSAG 
admission New comorbidities developed after discharge




% of AP 
cohort
% of 





AMI 2.7 1.2 <0.001 3.7 1.8 <0.001 2.09 1.4 3.12
Cerebral vascular 
accident
1.9 1.7 0.555 3.5 2.2 0.021 1.58 1.07 2.35
Congestive heart 
failure
2.3 0.4 <0.001 2.5 0.8 <0.001 3.11 1.83 5.28
Connective tissue 
disorder




1.8 0.2 <0.001 3.9 0.4 <0.001 10.7 5.74 19.94
Liver disease and 
severe liver disease
0.5 0.1 0.004 0.6 0.1 0.003 5.3 1.55 18.14
Peptic ulcer 1.9 0.3 <0.001 1.6 0.3 <0.001 5.06 2.38 10.74
Peripheral vascular 
disease
1.5 0.6 0.007 1.3 0.5 0.002 2.86 1.41 5.81
Pulmonary disease 3.8 1.1 <0.001 2.5 1.6 0.033 1.65 1.04 2.62
Cancer and 
metastatic cancer
7.2 2.8 <0.001 8.4 5.4 <0.001 1.62 1.25 2.11
Renal disease 1 0.2 0.001 1.1 0.1 <0.001 9.15 2.95 28.43
The percentage of patients and controls who developed each specified comorbidity in the 5 years before and 5 years after the index AP 
episode is presented. The OR as well as the 95% CI for the development of each comorbidity after the AP episode are included. Total number 
of patients from the AP cohort: 1150; total number of controls: 3450. The p values were obtained by applying the two-sample z test. P<0.05 
was considered significant.
AMI, acute myocardial infarction; AP, acute pancreatitis; SICSAG, Scottish Intensive Care Society Audit Group software; OR, odds ratio.
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long-term outcomes with a critical care stay exceeding 20 
days, in that individuals with less associated comorbidity 
at AP onset may be more resilient to a prolonged crit-
ical care admission. This finding is in contrast to data on 
long-term survival in all ICU patients, where prolonged 
admission was associated with a shorter long-term 
survival.32 33 However, the positive association between 
duration of organ support in ICU and post-ccAP survival 
is likely subject to iatrogenic influences. For example, a 
willingness to persist with organ support in critical care by 
the physician-led multidisciplinary team in those without 
significant medical comorbidity prior to ICU admission 
may result in organ support being continued for longer, a 
form of survivor treatment selection bias.34
We observed that gallstone aetiology had a less nega-
tive effect on prognosis. While this might be explained by 
the additional burden of morbidity and mortality carried 
by alcohol misuse, the other key cause of AP,35–37 our 
data imply that gallstone AP requiring critical care has 
less severe long-term consequences. This is in contrast to 
previous studies by others, where, in acute AP, a gallstone 
aetiology was associated with more severe MODS than 
alcohol-induced cases,38 and separately no effect of gall-
stone aetiology on long-term prognosis after accounting 
for the detrimental impact of alcohol.29 It is important to 
note that alcohol-related AP was not specifically known in 
our study population.
A strength of this study is that the applicability of these 
observations to all ccAP survivors has been enhanced by 
using primary data from a population basis rather than a 
single centre, in collaboration with Farr@Scotland. This 
UK-wide network was created to facilitate the storage, 
sharing and analysis of population and health-related 
data sets in an environment that protects patient confi-
dentiality and data security.39 The employment of this 
resource facilitated the achievement of larger sample 
population than would have been possible with a single-
centre study and reduced the risk of the results being 
modified by, for example, regional variations in treat-
ment or population demographics.40 41 Matching each 
member of the ccAP cohort by year of birth, deprivation 
and sex to three individuals sampled from the remaining 
general population diminished any potential influence of 
national secular trends in the population incidence on 
the specific outcomes measured.
We acknowledge specific limitations of our study. First, 
the use of pre-existing national databases requires an 
acceptance of low amounts of missing data that might 
have been avoided had it been possible to prospectively 
capture all primary data. However, the expense and 
time needed to do that would make a study of this size 
extremely unwieldy, and we regard our approach to be 
preferable to that, at this stage. The incidence of missing 
data was very low, with the exception of APACHE II scores. 
In order to overcome data inaccuracies, only gallstone 
aetiology was specifically noted. Our experience of using 
these records to correctly attribute alcohol aetiology have 
not been sufficiently reliable as a foundation for a robust 
analysis. Although not possible within the limitations of 
the current study, this will be an important consideration 
in advancing this research. Because there was uncertainty 
in our attribution of ccAP aetiology, with the exception of 
those diagnosed with gallstones, coupled with our use of 
relatively healthy controls from the general population, we 
were unable to analyse future causes of death and survival 
bias based on that factor. Insufficient detail in this data set 
precluded a robust analysis regarding the frequency of 
recurrent episodes of AP in the cohort, because it was not 
possible to distinguish repeat hospital admissions due to 
complications arising from the index episode from true 
de novo recurrent episodes. This would be addressed by 
a prospective study. Finally, the analysis of existing and 
new comorbidities was limited by relatively low propor-
tions of patients affected by each comorbidity. The value 
of replicating these findings using larger patient cohorts 
would need to be weighed against the practical chal-
lenges but should be considered. Further clarification of 
this phenomenon, and the impact on other body systems, 
is in progress through a prospective experimental medi-
cine cohort study.42 The identification of specific goals for 
intervention in the follow-up period after AP will require 
that detailed assessment of alterations in patients’ physio-
logical status over time.
In conclusion, long-term outcomes after AP requiring 
critical care are influenced by pre-existing patient char-
acteristics and specific factors associated with an episode 
of critical care admission. Persisting metabolic derange-
ment after ccAP is associated with premature death. The 
persistent deleterious impact of severe AP on survival is 
multifactorial, and further mechanistic and epidemiolog-
ical investigation is required.
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